Caredx, Inc. current report, 16 December 2015

Full document

Business Context and Reporting Period

Company: CareDx, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: December 16, 2015
Event: Entry into a material definitive agreement and announcement of a public exchange offer to acquire Allenex AB, a Swedish company listed on Nasdaq Stockholm specializing in genomic HLA diagnostic tests for organ transplant patients.

Key Financial Metrics and Transaction Structure

Total Purchase Price: Approximately $35 million (including milestones), consisting of cash and CareDx common stock.
Acquisition Target: Approximately 78% of Allenex AB outstanding shares via Conditional Share Purchase Agreements with majority shareholders, with a public offer for the remaining shares.
Consideration to Majority Shareholders:

  • Cash: SEK 1.191 per share (~$0.14).
  • Contingent Cash: Up to SEK 0.540 per share (~$0.06), subject to commercial/financial milestones in Q4 2015 and 2016.
  • Stock: 0.01298 shares of CareDx common stock per Allenex share.
Consideration to Public Shareholders (Offer Alternatives):
  • All Cash: SEK 2.50 per share (~$0.29).
  • Mixed: SEK 1.731 per share (~$0.20) plus 0.01298 shares of CareDx common stock per Allenex share.
Equity Issuance: Up to 1,560,807 shares of CareDx common stock (approx. 11.6% of post-offer outstanding shares) if the mixed alternative is fully accepted.
Financing: CareDx anticipates entering a loan agreement to finance the cash portion, collateralized by substantially all assets, with operating and financial covenants.

Material Changes and Conditions

The filing announces a strategic shift to create an international transplantation diagnostics company with presence in the US and Europe. The transaction is subject to several material conditions:

  • Acceptance Threshold: CareDx must acquire at least 78% of Allenex outstanding shares.
  • Material Adverse Effect: No undisclosed circumstances causing a material adverse effect on Allenex's sales, results, liquidity, or assets.
  • Regulatory/Legal: No legislation or court decisions rendering the offer impossible or significantly impeded.
  • Termination Date: The agreements with majority shareholders terminate automatically if the offer is not declared unconditional by April 8, 2016.
  • Compulsory Acquisition: If CareDx acquires >90% of shares, it intends to initiate a compulsory acquisition of remaining shares and delist Allenex from Nasdaq Stockholm.

Outlook, Risks, and Management Commentary

Strategic Rationale: The acquisition aims to combine CareDx's post-transplant monitoring capabilities with Allenex's pre-transplant HLA matching diagnostics, creating cross-selling opportunities and a stronger global footprint.
Key Risks:

  • Integration Challenges: CareDx has limited experience with acquisitions and cross-border integration; failure to integrate could harm operations.
  • Product Performance: Success depends on Allenex's new product, QTYPE, which faces risks regarding clinical validation, regulatory approval, and commercial acceptance.
  • Financial Impact: The transaction will deplete cash reserves, incur debt with restrictive covenants, and dilute existing shareholders (up to 11.6%).
  • Market Competition: Allenex faces competition from producers of automated typing processes and new technologies.
  • Impairment: Goodwill and intangibles acquired may be subject to future impairment charges.
  • Uncertainty: Failure to meet conditions or complete the offer could negatively impact CareDx's stock price.
Management Commentary: Management expects the combination to create a strong presence in both the US and Europe but acknowledges the risks of dilution, debt, and integration complexity.

Investor Verification Checklist

  • Verify the final acceptance rate of the public offer to determine if the 78% threshold is met.
  • Review the specific terms of the anticipated loan agreement, including interest rates, covenants, and collateral requirements.
  • Monitor the performance of Allenex's QTYPE product and its regulatory status.
  • Assess the impact of the 11.6% potential dilution on CareDx's earnings per share.
  • Track the satisfaction of the contingent cash milestones for the majority shareholders.
  • Confirm whether the April 8, 2016 deadline for declaring the offer unconditional is met.